Chest
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of patients. Several studies have shown that acute exacerbations (AEs) decrease health-related quality of life, pulmonary function and survival of COPD patients. The objective of the present study was to examine the effects of a physical therapy program on quality of life in COPD patients hospitalized due to an acute exacerbation. ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Angela Ruíz-SáezNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Dyspnea, the most distressing symptom experienced by COPD patients, is not always adequately relieved by bronchodilator monotherapy. The BLAZE study evaluated the superiority of QVA149, a dual bronchodilator combining the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium, versus placebo and tiotropium for improvement in direct patient-reported dyspnea as assessed by the innovative self-administered computerized baseline and transition dyspnea index (SAC-BDI/TDI). ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Consultant fee, speaker bureau, advisory committee, etc.: consultant for GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion, Grant monies (from industry related sources): receiving grants for clinical trials from Boehringer Ingelheim, Novartis, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Critical Care Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: TTP was once recognized for its classic pentad features of fever, thrombocytopenia, microangiopathic hemolytic anemia, neurologic dysfunction and renal impairment. However TTP may present with atypical features and the diagnosis may be unrecognized. ⋯ The following authors have nothing to disclose: Ma. Theresa Bautista, Jay Steingrub, Ramakant sharmaNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) is being developed for treatment of COPD. This study assessed the efficacy and safety of two twice-daily (BID) FDCs vs monotherapies and placebo. ⋯ Dave Singh: Grant monies (from industry related sources): AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck, Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc. Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc., Grant monies (from industry related sources): E D Bateman's has received payment from Almirall for participation in clinical trials Stephanie Korn: Consultant fee, speaker bureau, advisory committee, etc.: Almirall Cristina Serra: Employee: Almirall S.A. Eduard Molins: Employee: Almirall S.A. Cynthia Caracta: Employee: Almirall S.A. Esther Garcia Gil: Employee: Almirall S.A. Anne Leselbaum: Employee: Almirall S.A.This abstracts presents the results of a double blind, randomized Phase III trial of a fixed combination of two products, each of which are approved as monotherapies for the treatment of COPD.
-
Respiratory InfectionsSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: INTRODUCTION Elevated ADA levels in pleural fluid are highly suggestive of pleural tuberculosis. In fact, values above 35UL in our practice present levels of sensitivity and specificity > 90%. However, sometimes we find very high levels of ADA Pleural uncommon for tuberculosis. Is there an upper limit level of ADA to justify the possibility of another process? ⋯ The following authors have nothing to disclose: Patricia Lazo Meneses, Esteban Perez Rodriguez, Carolina Gotera, Jonathan Cámara Fernández, Deisy Barrios Barreto, Salvador Diaz Lobato, Sagrario Mayoralas Alises, Eva Mañas Baena, Rosa Mirambeaux VillalonaNo Product/Research Disclosure Information.